DMW – Klinischer Fortschritt, Table of Contents Dtsch Med Wochenschr 2014; 139(23): 1204-1206DOI: 10.1055/s-0034-1370011 Endokrinologie & Diabetologie | Commentary Endokrinologie © Georg Thieme Verlag KG Stuttgart · New York Lipoprotein(a) als Arteriosklerose-Risikofaktor Lipoprotein(a): a risk factor for atherosclerosis S. Fischer 1 Medizinische Klinik und Poliklinik III des Universitätsklinikums Dresden , U. Julius 1 Medizinische Klinik und Poliklinik III des Universitätsklinikums Dresden , S. Tselmin 1 Medizinische Klinik und Poliklinik III des Universitätsklinikums Dresden , U. Schatz 1 Medizinische Klinik und Poliklinik III des Universitätsklinikums Dresden , S. R. Bornstein 1 Medizinische Klinik und Poliklinik III des Universitätsklinikums Dresden › Author Affiliations Recommend Article Abstract Buy Article Schlüsselwörter Schlüsselwörtererhöhter Lipoprotein(a)-Spiegel - Arteriosklerose-Risiko - Diagnostik - Therapie - Lipoprotein-Apherese Keywords Keywordslipoprotein(a) - atherosclerosis risk - diagnostic - therapy - lipoprotein-apheresis Full Text References Literatur 1 Erqou S, Kaptoge S, Perry PL et al. Emerging Risk Factors Collaboration. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009; 302: 412-423 2 Gurdasani D, Sjouke B, Tsimikas S et al. Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC-Norfolk prospective population study. Arterioscler Thromb Vasc Biol 2012; 32: 3058-3065 3 Jaeger BR, Richter Y, Nagel D et al. Group of Clinical Investigators. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med 2009; 6: 229-239 4 Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol 2014; 11: 470-477 5 Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG. Extreme lipoprotein (a) levels and improved cardiovascular risk prediction. J Am Coll Cardiol 2013; 19: 1146-1156 6 Kassner U, Thomas HP, Steinhagen-Thiessen E. Lipoprotein(a): epidemiology and therapeutic approaches. Dtsch Med Wochenschr 2000; 125: 1337-1343 7 Kraft HG, Utermann G. Primäre Dyslipoproteinämien, Lipoprotein(a). 3. Auflage. In: Schwandt P, Parhofer KG, eds, Handbuch der Fettstoffwechselstörungen. Stuttgart, New York: Schattauer; 2006: 216-230 8 Leebmann J, Roeseler E, Julius U et al. Pro(a) LiFe Study Group. Lipoprotein apheresis in patients with maximally tolerated lipid lowering therapy, lipoprotein(a)- hyperlipoproteinemia, and progressive cardiovascular disease: Prospective observational multicenter study. Circulation 2013; 128: 2567-2576 9 Nordestgaard BG, Chapman MJ, Ray K et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010; 31: 2844-2853 10 Parhofer KG. Update Fettstoffwechselstörungen. Internist 2013; 54: 1089-1101 11 Rosada A, Kassner U, Vogt A et al. Does regular lipid apheresis in patients with isolated elevated lipoprotein(a) levels reduce the incidence of cardiovascular events?. Artificial Organs 2014; 38: 135-141 12 Seed M, Hoppichler F, Reavely D et al. Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in familial hypercholesterinemia. N Engl J Med 1990; 322: 1494-1499 13 Tselmin S, Julius U, Müller G et al. Cardiovascular events in patients with increased lipoprotein(a) – retrospective data analysis in an outpatient department of lipid disorders. Atherosclerosis Suppl 2009; 10: 79-84 14 von Dryander M, Fischer S, Passauer J et al. Differences in the atherogenic risk of patients, treated by lipoprotein apheresis according to their lipid pattern. Atherosclerosis Suppl. 2013; 14: 39-44
